Pharmaceutics

Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections

Retrieved on: 
Tuesday, February 27, 2024
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, ESBL, GAIN, Second Continental Congress, Urinary tract infection, Supervisory board, Pharmaceutics, Cutis, Partnership, Food, Pyelonephritis, Gram-negative bacteria, Patient, Congress, Medication, Pharmaceutical industry

Allecra Therapeutics (“Allecra”), a biopharmaceutical company developing novel therapies to combat antibiotic resistance, announced today that the U.S. Food and Drug Administration (FDA) has approved EXBLIFEP® (cefepime/enmetazobactam), as a treatment for complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years and older.

Key Points: 
  • Allecra Therapeutics (“Allecra”), a biopharmaceutical company developing novel therapies to combat antibiotic resistance, announced today that the U.S. Food and Drug Administration (FDA) has approved EXBLIFEP® (cefepime/enmetazobactam), as a treatment for complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years and older.
  • Allecra has also received a five-year marketing exclusivity extension from the FDA as part of the Generating Antibiotic Incentives Now Act (GAIN Act).
  • "Receiving FDA approval is a tremendous achievement for Allecra and a testament to the hard work and dedication of a small, yet highly focused team of individuals.
  • Enmetazobactam was first discovered by Orchid Pharma and all rights outside India were assigned to Allecra Therapeutics in 2013.

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

Retrieved on: 
Thursday, February 15, 2024
Neoplasm, Doctor of Philosophy, Immunotherapy, SCCA, News, Pharmaceutics, Destiny, PR, Optimism, Poster, Anal cancer, Pancreatic cancer, Anal, CEACAM6, Brigham and Women's Hospital, Bristol Myers Squibb, Therapy, Immune system, Pelareorep, International, Breast cancer, Fast track (FDA), Serology, AIO, Hospital, Hope, Principal investigator, HGG, Conference, Safety, Biomarker, Tumor microenvironment, Patent, Clinical trial, Survival, Harvard Medical School, Acute lymphoblastic leukemia, Injection, MSI, MD, BioNTech, FDA, TSX, Cancer, Entrepreneurship, Prevalence, American depositary receipt, Anal canal, Patient, Cone Health Women's Hospital, ONC, Pharmaceutical industry

According to the American Association for Cancer Research "Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment."

Key Points: 
  • According to the American Association for Cancer Research "Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment."
  • Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is developing pelareorep, a unique immunotherapy with the power to awaken the immune system and unlock its antitumor potential.
  • It is committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
  • Bristol-Myers Squibb and Fate Therapeutics are some of the other key patent filers in cancer immunotherapy."

2024 Feather in Her Cap and High Flyer Award Winners Named for Outstanding Achievements in Animal Health Industry

Retrieved on: 
Tuesday, January 16, 2024
Philanthropy, Health, Consumer, Women, Foundation, Veterinary, Animal Health, Woman, Osteoarthritis, Therapy, Frunevetmab, Multimedia, Female, Intellectual disability, University, Engagement, Mentorship, Dog, Pharmaceutics, Elanco, Veteran, Cat, DVM, Boehringer Ingelheim, ELAN, Doctor of Philosophy, Veterinary medicine, Highflyer, Feather, Marketing, Formulation, Inclusion, Education, Management

The Feather in Her Cap Association, Inc. and 300 industry leaders honored 11 women for their outstanding career achievements in Animal Health at the seventh annual Feather in Her Cap awards ceremony.

Key Points: 
  • The Feather in Her Cap Association, Inc. and 300 industry leaders honored 11 women for their outstanding career achievements in Animal Health at the seventh annual Feather in Her Cap awards ceremony.
  • Andrea J. Gonzales Ph.D., vice president of Global Companion Animal Therapeutics at Zoetis, Inc., (NYSE: ZTS) was awarded the 2024 Feather in Her Cap award and Katharina Bohnenblust Ph.D., senior director, head of Formulation Development at Elanco Animal Health (NYSE: ELAN) was this year’s recipient of the 2024 High Flyer award.
  • Each year, the Feather in Her Cap award winner chooses an animal-related non-profit organization to receive a $5,000 donation.
  • The nomination process will reopen in Q3 of 2024 to celebrate more outstanding women in Animal Health in 2025.

GlobalData Names BostonGene Leading Innovator in AI-Driven Drug Repurposing

Retrieved on: 
Wednesday, January 3, 2024
Technology, Genetics, Software, Biotechnology, Health, Pharmaceutical, General Health, Artificial Intelligence, Oncology, GlobalData, Drug discovery, Medicine, Drug development, Research, Pharmaceutical industry, Artificial intelligence, Pharmaceutics, Machine learning, Patient, Therapy, Algorithm, Medical device

BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced that it has been named a leading innovator in AI drug repurposing in a recent report published in Pharmaceutical Technology, part of the GlobalData network.

Key Points: 
  • BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced that it has been named a leading innovator in AI drug repurposing in a recent report published in Pharmaceutical Technology, part of the GlobalData network.
  • The article, " Innovators in AI Drug Repurposing: Pioneering AI in the Pharmaceutical Industry ," showcases BostonGene at the forefront of innovation by leading in both geographical reach and application diversity.
  • GlobalData analyzed over 260 companies, spanning technology vendors, established pharmaceutical companies and up-and-coming start-ups engaged in the development and application of drug repurposing AI to determine their leadership ranking.
  • "We are honored to be recognized as innovators in AI drug repurposing," said Andrew Feinberg, President and CEO at BostonGene.

Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction

Retrieved on: 
Thursday, December 21, 2023
Bar-Ilan University, Cocaine, Depression, FDA, Crime, PLUR, Pharmaceutics, Plural, PLX, Brain, Drug, Research, Rat, BIRAD, PTSD, Anxiety, U.N, Neurogenesis, Cell, Neuron, PAD, Pharmaceutical industry

Under the agreement, Bar-Ilan University via BIRAD will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction.

Key Points: 
  • Under the agreement, Bar-Ilan University via BIRAD will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction.
  • The agreement stems from a collaboration between Pluri and Bar-Ilan University researchers that presented compelling findings.
  • The studies evaluated PLX-PAD cells’ efficacy in treating cocaine addiction in animal models.
  • Across North America and Europe, demand for treatment has steadily increased over the last decade, according to the U.N. Office on Drugs and Crime.

Critical agreement paves way for new model to accelerate access to important antibiotics for serious bacterial infections

Retrieved on: 
Tuesday, September 12, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, CHAI, US Foods, Gram, Infection, European Medicines Agency, National Rural Development Partnership, Pharmaceutics, AMR, PQ, Cephalosporin, Patient, Tuberculosis, Diagnosis, WHO, Death, Food, World Health Organization, Essential medicines, Pharmaceutical industry, Shionogi, Orchid

Launched in June 2022, the project represents a new model for bridging global gaps in equitable access to important antibiotics.

Key Points: 
  • Launched in June 2022, the project represents a new model for bridging global gaps in equitable access to important antibiotics.
  • Even though populations in low- and middle-income countries face a high burden of death from drug-resistant bacterial infections, their access to antibiotics with activity against resistant bacteria is usually delayed by more than a decade .
  • That situation may worsen given that the number of serious, potentially life-threatening, infections due to carbapenem-resistant bacteria has been growing across multiple regions , including South Asia and Latin America.
  • By addressing barriers that have historically limited the availability of important antibiotics in low- and middle-income countries, this innovative project aims to accelerate appropriate access for an affordable, quality-assured antibiotic to treat drug-resistant Gram-negative infections.

CordenPharma Establishes World-Class Technology & Science Advisory Board of Experts Across Six Technology Platforms

Retrieved on: 
Wednesday, July 26, 2023
Biochemistry, Business development, Drug development, University, Drug delivery, Organic chemistry, Approved Drug Products with Therapeutic Equivalence Evaluations, Institute of technology, Biotechnology, Lipid, MBA, OSD, Technical University of Berlin, RNA, University of Bonn, University of Graz, CDMO, Professor, Machine learning, Pharmaceutics, Knowledge, Growth, AI, API, LNP, Solid lipid nanoparticle, Oligonucleotide, Bipolar Integrated Technology, Pharmacology, Peptide, Fine chemical, Vaccine, Management, Biopharmaceutical, Chemistry, Ludwig Maximilian University of Munich

CDMO CordenPharma establishes world-class Technology & Science Advisory Board of experts across 6 technology platforms.

Key Points: 
  • CDMO CordenPharma establishes world-class Technology & Science Advisory Board of experts across 6 technology platforms.
  • The formation of the Technology & Science Advisory Board was born out of CordenPharma's commitment to stay at the forefront of the pharmaceutical and biotechnology industries.
  • Their collective expertise will provide valuable insights into emerging trends, cutting-edge technologies, and regulatory advancements across all six CordenPharma technology platforms .
  • Dr. Michael Quirmbach, CEO & President at CordenPharma, said: "CordenPharma is honored to have the opportunity to work with these distinguished scientific experts.

CordenPharma Establishes World-Class Technology & Science Advisory Board of Experts Across Six Technology Platforms

Retrieved on: 
Wednesday, July 26, 2023
Biochemistry, Business development, Drug development, University, Drug delivery, Organic chemistry, Approved Drug Products with Therapeutic Equivalence Evaluations, Institute of technology, Biotechnology, Lipid, MBA, OSD, Technical University of Berlin, RNA, University of Bonn, University of Graz, CDMO, Professor, Machine learning, Pharmaceutics, Knowledge, Growth, AI, API, LNP, Solid lipid nanoparticle, Oligonucleotide, Bipolar Integrated Technology, Pharmacology, Peptide, Fine chemical, Management, Biopharmaceutical, Chemistry, Ludwig Maximilian University of Munich

The formation of the Technology & Science Advisory Board was born out of CordenPharma's commitment to stay at the forefront of the pharmaceutical and biotechnology industries.

Key Points: 
  • The formation of the Technology & Science Advisory Board was born out of CordenPharma's commitment to stay at the forefront of the pharmaceutical and biotechnology industries.
  • CordenPharma's TSAB brings together eight scientific experts from various disciplines, including chemistry, pharmacology, biotechnology, and regulatory affairs.
  • Their collective expertise will provide valuable insights into emerging trends, cutting-edge technologies, and regulatory advancements across all six CordenPharma technology platforms .
  • Dr. Michael Quirmbach, CEO & President at CordenPharma, said: "CordenPharma is honored to have the opportunity to work with these distinguished scientific experts.

Zerion Pharma's Dispersome® technology published in two peer-reviewed papers through partnerships with pharmaceutical companies

Retrieved on: 
Thursday, June 8, 2023
Pharmaceutics, Partnership, Nimodipine, CSO, Bayer, Pharmacy, Publication, Novartis, Canadian International Council, Whey, Pharmaceutical industry

COPENHAGEN, Denmark, June 8, 2023 /PRNewswire/ -- Zerion Pharma A/S ('ZERION') today announces the publication of joint experimental work on its Dispersome® technology in the International Journal of Pharmaceutics and Pharmaceutical Research, two peer-reviewed papers.

Key Points: 
  • COPENHAGEN, Denmark, June 8, 2023 /PRNewswire/ -- Zerion Pharma A/S ('ZERION') today announces the publication of joint experimental work on its Dispersome® technology in the International Journal of Pharmaceutics and Pharmaceutical Research, two peer-reviewed papers.
  • The work behind the publications originated from two partnership projects, one with Bayer AG and one with Novartis Pharma AG.
  • Both papers demonstrated the exceptional performance of the Dispersome® technology, resulting in very significant increases in drug solubility.
  • Especially for new technologies such as the Dispersome® technology, it is of utmost importance to publish such findings, which ultimately will help to generate more confidence in the technology", says Korbinian Löbmann, CSO of ZERION.

Zerion Pharma's Dispersome® technology published in two peer-reviewed papers through partnerships with pharmaceutical companies

Retrieved on: 
Thursday, June 8, 2023
Pharmaceutics, Partnership, Nimodipine, CSO, Bayer, Pharmacy, Publication, Novartis, Canadian International Council, Whey, Pharmaceutical industry

COPENHAGEN, Denmark, June 8, 2023 /PRNewswire/ -- Zerion Pharma A/S ('ZERION') today announces the publication of joint experimental work on its Dispersome® technology in the International Journal of Pharmaceutics and Pharmaceutical Research, two peer-reviewed papers.

Key Points: 
  • COPENHAGEN, Denmark, June 8, 2023 /PRNewswire/ -- Zerion Pharma A/S ('ZERION') today announces the publication of joint experimental work on its Dispersome® technology in the International Journal of Pharmaceutics and Pharmaceutical Research, two peer-reviewed papers.
  • The work behind the publications originated from two partnership projects, one with Bayer AG and one with Novartis Pharma AG.
  • Both papers demonstrated the exceptional performance of the Dispersome® technology, resulting in very significant increases in drug solubility.
  • Especially for new technologies such as the Dispersome® technology, it is of utmost importance to publish such findings, which ultimately will help to generate more confidence in the technology", says Korbinian Löbmann, CSO of ZERION.